Pharmaceuticals

As a deadly superbug spreads, BioVersys's BV100 enters late-stage trials, backed by promising data and a novel scientific approach to combat resistance.

Immunome announces stellar Phase 3 data for its desmoid tumor drug, varegacestat, and details a robust, well-funded ADC pipeline aimed at solid tumors.

Finance and governance powerhouse Suzanne Nora Johnson joins Wellcome Leap's board, a strategic move to supercharge its mission to solve health crises.

A unique $4M award program aims to solve a critical funding gap, accelerating high-risk, high-reward cancer therapies from academic labs to patients.

As AI reshapes how patients get health info, new services aim to protect brands from inaccuracy, compliance risks, and reputational damage.

A new 'scar-less' protein purification technology promises to slash development timelines for complex biologics, accelerating the path to new medicines.

A novel sputum test could end the trial-and-error approach for millions with chronic respiratory disease, promising a new era of personalized medicine.

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

As SIGA prepares to unveil its 2025 financials, investors are focused on the future of its Tpoxx contracts and its role in global biodefense strategy.

With promising clinical data for its heart disease treatments, Lexeo Therapeutics aims to capture investor attention at the upcoming Leerink conference.

Former Novo Nordisk CSO Marcus Schindler joins Cradle, validating AI's role in accelerating drug discovery and reshaping traditional pharmaceutical R&D.

After a kidney trial setback, CalciMedica's lead drug Auxora shows strong promise for acute pancreatitis, but a tight cash runway looms over its future.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

Esperion's $75M+ deal for Corstasis and its novel nasal diuretic, Enbumyst, targets a $4B market and a new era of at-home edema management.

Greenwich LifeSciences' Phase III trial for its GLSI-100 immunotherapy is enrolling patients faster than ever, with early data echoing past success.

A novel CRISPR-based therapy safely targets deadly E. coli in the gut, showing promise in the fight against antibiotic resistance and for protecting cancer patients.

Peli BioThermal and Polar Group partner to upgrade Brazil's pharma logistics, tackling a booming market and ensuring safer delivery of advanced medicines.

Popular weight-loss drugs are linked to fewer ER visits for chronic migraine, a new study finds, sparking hope and questions about a new treatment frontier.